These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 20118492)
21. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients. Bader T; Hughes LD; Fazili J; Frost B; Dunnam M; Gonterman A; Madhoun M; Aston CE J Viral Hepat; 2013 Sep; 20(9):622-7. PubMed ID: 23910646 [TBL] [Abstract][Full Text] [Related]
22. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566 [TBL] [Abstract][Full Text] [Related]
23. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR. Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144 [TBL] [Abstract][Full Text] [Related]
24. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297 [TBL] [Abstract][Full Text] [Related]
25. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis. Zhu Q; Li N; Han Q; Zhang P; Yang C; Zeng X; Chen Y; Lv Y; Liu X; Liu Z Antiviral Res; 2013 Jun; 98(3):373-9. PubMed ID: 23603497 [TBL] [Abstract][Full Text] [Related]
26. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses. Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559 [TBL] [Abstract][Full Text] [Related]
27. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561 [TBL] [Abstract][Full Text] [Related]
28. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296 [TBL] [Abstract][Full Text] [Related]
29. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070 [TBL] [Abstract][Full Text] [Related]
30. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160 [TBL] [Abstract][Full Text] [Related]
31. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331 [TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800 [TBL] [Abstract][Full Text] [Related]
33. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136 [TBL] [Abstract][Full Text] [Related]
34. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients]. Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487 [TBL] [Abstract][Full Text] [Related]
37. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F; Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475 [TBL] [Abstract][Full Text] [Related]
38. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856 [TBL] [Abstract][Full Text] [Related]
39. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV; Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B; J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]